Abstract
Pravastatin treatment of combined hyperlipidemia lowers low-density lipoprotein effectively; nicotinic acid lowers remnant cholesterol and raises high-density lipoprotein. A combination of these 2 drugs may be indicated for optimal treatment of lipoprotein abnormalities in combined hyperlipidemia.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Anticholesteremic Agents / therapeutic use*
-
Cholesterol / blood
-
Cholesterol, HDL / blood
-
Cholesterol, LDL / blood
-
Cross-Over Studies
-
Humans
-
Hyperlipidemias / drug therapy*
-
Middle Aged
-
Niacin / therapeutic use*
-
Pravastatin / therapeutic use*
-
Risk Factors
-
Triglycerides / blood
Substances
-
Anticholesteremic Agents
-
Cholesterol, HDL
-
Cholesterol, LDL
-
Triglycerides
-
Niacin
-
Cholesterol
-
Pravastatin